Navigation Links
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH)

nticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a long half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function.

About PRT060128 -- Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral formulation and a single ascending dose study with the IV formulation. Based on positive results from these studies, Portola intends to initiate its Phase II program in the second half of 2007.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascul
'"/>




Page: 1 2 3

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:4/30/2015)... WOODBRIDGE, ON , April 30, 2015 /PRNewswire/ ... a specialty pharmaceutical company with a focus on ... health, announced its operational highlights and financial results ...  All dollar amounts referenced herein are in Canadian ... in 2014 have been significant, with the right ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
(Date:4/30/2015)... Calif. , April 30, 2015  IRIDEX Corporation ... release its first quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, May ... quarter and other business developments. Interested parties ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... ProStrakan Group plc (LSE: PSK) today announced the ... the first rapidly-disintegrating tablet placed under the tongue for ... (F.D.A.) approved ABSTRAL, an opioid analgesic, in January 2011 ... patients, 18 years of age or older, ...
... Daiichi Sankyo, Inc. (DSI) announced today that John P. ... Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is ... the past 14 years. "John,s experiences within ... him well for his new role and responsibility," said Joseph ...
Cached Medicine Technology:ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 2ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 3ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 4ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 5ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 6ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 7John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. 2
(Date:5/2/2015)... 02, 2015 ProText Kinetic 2 is a ... Final Cut Pro X. ProText Kinetic 2 features 40 ... Final Cut Pro X . Easily create interactive text ... Film Studios' ProText Kinetic 2. , Using ProText Kinetic is ... two ProText Kinetic presets in the FCPX timeline. Playback ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... Liverpool, Ohio (PRWEB) May 02, 2015 ... East Liverpool City Hospital (ELCH) gathered to celebrate improvements ... of River Valley Health Partners (RVHP), had zero acquired ... zero urinary catheter associated infections. ELCH was also recently ... , The management team at ELCH credited the teamwork ...
(Date:5/2/2015)... 2015 As a nonsurgical staple ... the face, neck and décolleté, radiofrequency energy is ... potential for the success of vulvovaginal rejuvenation. In ... Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory Board ... that ThermiGyn’s temperature controlled radio frequency, specifically that ...
(Date:5/2/2015)... With the success that Veatch Dental Consulting has ... Neida Miranda and Alex Shields to the team. With Neida ... years of combined experience working with dentists to ensure their ... for 8 years. She was certified as dental assistant ... positive attitude and showing the importance of oral hygiene to ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2
... , , FRIDAY, May 23 (HealthDay News) -- Patients with ... a few years of diagnosis may finally have some ... of the drug pirfenidone improved the lung function and ... idiopathic pulmonary fibrosis (IPF). , "Patients look to any ...
... When Jon Ziefert and Steve Smith were,recovering from ... food gift baskets. "Some were healthy but most ... ... was highly,perishable. So they had to give most of ... and other high-sugar, high-fat foods simply had no,place in ...
... Jorge Alan Rodriguez,Sanchez, 32, was indicted by ... distribute controlled substances through the operation of an,illegal ... Alice S. Fisher and U.S. Attorney Patrick L. ... Sanchez is also charged with four counts ...
... Follow Along Online, WICHITA, Kan., May 22 ... of the world -- Mount Everest -- that was ... another,mountain? How about climb to the highest point of ... 50 days or less., (Photo: http://www.newscom.com/cgi-bin/prnh/20080522/AQTH080LOGO ), ...
... HOUSTON, May 22 The 39th gathering of the ... a 60-member West,African choir to help celebrate the success ... between Methodists in Texas and,Cote d,Ivoire (Ivory Coast). The ... 25-28., A proclamation reading and signing on May ...
... generated by Shahin Rafii and colleagues, at Weill Medical College ... cancer cells and mice, have shed doubt on the recently ... colon cancer stem cells a term given to the ... thought to be able to give rise to a new ...
Cached Medicine News:Health News:Drug for Deadly Lung Disease Shows Promise 2Health News:Drug for Deadly Lung Disease Shows Promise 3Health News:Cancer Survivors Develop Healthy Food Gift Business 2Health News:California Man Indicted For Conspiracy In Operating Internet Pharmacy 2Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 2Health News:Denver Schoolteacher to Climb Summits of 50 States in 50 Days 3Health News:Local Methodists Host West African Choir, South African Leader at Historic Conference 2
The TS100-F trinocular model comes with a photo port that accepts Nikon's FX-III series photomicrographic systems, CCTV camera, or digital camera....
... A standard laboratory microscope whose ... imagery combine to make it ... E400 is designed to fit ... the user to fit the ...
... incorporate the slight change in the difficulty ... letters derived from the best corrected visual ... ETDRS study. The original charts difficulty scores ... eyes. In addition to the revised arrangement ...
Created to simplify stereopsis screening in children. Based on principles of random dots. No glasses are necessary for this stereo test, and the child's eye movement can be easily observed....
Medicine Products: